Sinsin Pharmaceutical Co. Ltd
Sinsin Pharmaceutical Co., Ltd manufactures and sells pharmaceutical products in South Korea. It offers various medicinal products, such as plaster, aerosol, topical liquid, emollient, hygiene, and ointment products, as well as adhesive bandages, mosquito repellents, anti-perspirants, cooling sheets, bruise treatment creams, and other products. The company also develops transdermal drug delivery … Read more
Sinsin Pharmaceutical Co. Ltd (002800) - Net Assets
Latest net assets as of September 2025: ₩71.01 Billion KRW
Based on the latest financial reports, Sinsin Pharmaceutical Co. Ltd (002800) has net assets worth ₩71.01 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩136.11 Billion) and total liabilities (₩65.10 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩71.01 Billion |
| % of Total Assets | 52.17% |
| Annual Growth Rate | 8.45% |
| 5-Year Change | 17.22% |
| 10-Year Change | N/A |
| Growth Volatility | 16.17 |
Sinsin Pharmaceutical Co. Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Sinsin Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sinsin Pharmaceutical Co. Ltd (2016–2024)
The table below shows the annual net assets of Sinsin Pharmaceutical Co. Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩65.87 Billion | +6.09% |
| 2023-12-31 | ₩62.09 Billion | +4.01% |
| 2022-12-31 | ₩59.70 Billion | +8.69% |
| 2021-12-31 | ₩54.93 Billion | -2.26% |
| 2020-12-31 | ₩56.20 Billion | -0.30% |
| 2019-12-31 | ₩56.36 Billion | +3.34% |
| 2018-12-31 | ₩54.54 Billion | +4.64% |
| 2017-12-31 | ₩52.12 Billion | +51.38% |
| 2016-12-31 | ₩34.43 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sinsin Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 137.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩44.87 Billion | 68.12% |
| Common Stock | ₩7.59 Billion | 11.51% |
| Other Components | ₩13.41 Billion | 20.36% |
| Total Equity | ₩65.87 Billion | 100.00% |
Sinsin Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Sinsin Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MAISON POMMERY & ASSOCIES
PA:POMRY
|
$27.86 Million |
|
Igarashi Motors India Limited
NSE:IGARASHI
|
$27.86 Million |
|
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
|
$27.87 Million |
|
Reliance Communications Limited
NSE:RCOM
|
$27.87 Million |
|
Woodlands Financial Services Co
PINK:WDFN
|
$27.84 Million |
|
Arich Enterprise Co Ltd
TWO:4173
|
$27.84 Million |
|
ROKISKIO SURIS PC EO 029
F:YTV
|
$27.83 Million |
|
BOCOM International Holdings Company Limited
F:597
|
$27.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sinsin Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 62,295,048,410 to 65,873,603,030, a change of 3,578,554,620 (5.7%).
- Net income of 4,888,497,580 contributed positively to equity growth.
- Dividend payments of 910,230,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩4.89 Billion | +7.42% |
| Dividends Paid | ₩910.23 Million | -1.38% |
| Other Changes | ₩-399.71 Million | -0.61% |
| Total Change | ₩- | 5.74% |
Book Value vs Market Value Analysis
This analysis compares Sinsin Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.92x to 1.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2912.08 | ₩5600.00 | x |
| 2017-12-31 | ₩3435.58 | ₩5600.00 | x |
| 2018-12-31 | ₩3595.09 | ₩5600.00 | x |
| 2019-12-31 | ₩3715.31 | ₩5600.00 | x |
| 2020-12-31 | ₩3704.24 | ₩5600.00 | x |
| 2021-12-31 | ₩3620.62 | ₩5600.00 | x |
| 2022-12-31 | ₩3935.14 | ₩5600.00 | x |
| 2023-12-31 | ₩4106.33 | ₩5600.00 | x |
| 2024-12-31 | ₩4342.22 | ₩5600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sinsin Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.42%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.59%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 1.97x
- Recent ROE (7.42%) is above the historical average (5.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 12.90% | 7.65% | 0.84x | 2.00x | ₩998.22 Million |
| 2017 | 6.92% | 5.84% | 0.78x | 1.51x | ₩-1.61 Billion |
| 2018 | 5.31% | 4.54% | 0.59x | 1.98x | ₩-2.56 Billion |
| 2019 | 3.79% | 3.15% | 0.53x | 2.29x | ₩-3.50 Billion |
| 2020 | 0.65% | 0.54% | 0.57x | 2.10x | ₩-5.26 Billion |
| 2021 | -2.69% | -1.99% | 0.65x | 2.08x | ₩-6.97 Billion |
| 2022 | 7.39% | 4.80% | 0.76x | 2.03x | ₩-1.56 Billion |
| 2023 | 7.51% | 4.56% | 0.82x | 2.00x | ₩-1.55 Billion |
| 2024 | 7.42% | 4.59% | 0.82x | 1.97x | ₩-1.70 Billion |
Industry Comparison
This section compares Sinsin Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sinsin Pharmaceutical Co. Ltd (002800) | ₩71.01 Billion | 12.90% | 0.92x | $27.85 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |